Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656668 | 0.88 | ALDH1A1 (0.68) | KMT2AALDH1A1HPGDMAPK1AKR1C3 | |
| SCHEMBL2644969 | 0.86 | ALDH1A1 (0.61) | KMT2AALDH1A1HPGDTNIKMAPK1 | |
| SCHEMBL2710657 | 0.78 | ALOX5 (0.48) | ALDH1A1MAPK1PKMMGLLAKR1C3 | |
| SCHEMBL18788887 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HPGDMAPK1PKMMGLL | |
| SCHEMBL12615119 | 0.78 | RAB9A (0.51) | KMT2AALDH1A1MAPK1TDP1PKM | |
| SCHEMBL4733957 | 0.78 | IDO1 (0.50) | KMT2AALDH1A1HPGDMGLLAKR1C3 | |
| SCHEMBL18805067 | 0.78 | RAB9A (0.51) | KMT2AALDH1A1MAPK1TDP1PKM | |
| SCHEMBL24598513 | 0.77 | KMT2A (0.41) | KMT2AALDH1A1TNIKMAPK1TDP1 | |
| SCHEMBL136822 | 0.77 | NPC1 (0.60) | KMT2AALDH1A1HPGDTDP1DDB1 | |
| SCHEMBL22728437 | 0.76 | KMT2A (0.43) | KMT2AALDH1A1MAPK1TDP1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104892537-A | Ezetimibe intermediate and synthesis method of ezetimibe | JIANGXI SHIMEI PHARMACEUTICAL CO LTD | 2015-09-09 | — | — | CN | claimed |
| WO-2008057948-A2 | PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1677803-A2 | METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS | Forbes Medi-Tech Inc. (CA) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042692-A2 | A METHOD OF INHIBITING THE EXPRESSION OF GENES WHICH MEDIATE CELLULAR CHOLESTEROL INFLUX IN ANIMAL CELLS AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES USING CHOLESTEROL ABSORPTION INHIBITORS | FORBES MEDI-TECH INC. (CA) | 2005-05-12 | — | — | WO | claimed |
| WO-2005030225-A2 | METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS | FORBES MEDI-TECH INC. (CA) | 2005-04-07 | — | — | WO | claimed |
| EP-0792264-B1 | SULFUR-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 2002-02-27 | — | — | EP | claimed |
| US-12365881-B2 | Ketoreductase polypeptides | CODEXIS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4476222-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-113747885-B | Pharmaceutical combination formulation comprising ezetimibe and losartan | 韩美药品株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-107941959-A | A kind of liquid-phase chromatography method for separating Ezetimibe and its optical isomer | 北京嘉林药业股份有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-104892537-A | Ezetimibe intermediate and synthesis method of ezetimibe | JIANGXI SHIMEI PHARMACEUTICAL CO LTD | 2015-09-09 | — | — | CN | disclosed |
| WO-2005030225-A2 | METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS | FORBES MEDI-TECH INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| CN-1191372-C | Trans-2- (alkoxycarbonylethyl) for the synthesis of 1- (4-fluoro-phenyl) -3- (R) - [3(S) -hydroxy-3- (4-fluorophenyl) -propyl) ] -4 (S) - (4-hydroxyphenyl) -2-azetidinone | SCHERING CORP (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1500083-A | Enantioselective synthesis of azetidinone intermediate compounds | ���鹫˾ | 2004-05-26 | — | — | CN | disclosed |
| CN-1130342-C | Process for synthesis of beta-propanamide | SCHERING CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| CN-1330721-A | Resolution of trans-2-(alkoxycarbonylethyl)-laitams useful in synthesis of 1-(4-fluorophenyl)-3(R)-[3(s)-hydroxy-3-(flurophenyl)-propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone | SCHERING CORP (US) | 2002-01-09 | — | — | CN | disclosed |
| CN-1329592-A | Process for synthesis of beta-propanamide | SCHERING CORP (US) | 2002-01-02 | — | — | CN | disclosed |
| EP-0582469-A2 | Process for preparing taxol-type compound from beta-lactam precursors | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | KMT2A 3199/4885ALDH1A1 4818/4885HPGD 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.